<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A marked deficiency in antithrombin III (AT III) was demonstrated in a 39-year-old man suffering from recurrent thrombo-embolic problems </plain></SENT>
<SENT sid="1" pm="."><plain>The patient's father had died following a thrombo-embolic disorder </plain></SENT>
<SENT sid="2" pm="."><plain>A certain number of members of the family also showed evidence of a marked decrease in AT III levels </plain></SENT>
<SENT sid="3" pm="."><plain>Although it was not possible to study the patient's parents, it would seem reasonable to conclude that the diagnosis was one of hereditary deficiency in AT III </plain></SENT>
<SENT sid="4" pm="."><plain>The various aspects of this disorder discovered by Egeberg are reviewed: early <z:hpo ids='HP_0003674'>onset</z:hpo>, in several members of the same family, or recurrent thrombo-embolic problems, accompanied by a decrease in functional activity of one of the principal inhibitors of thrombin (AT III), with <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> transmission and treatment based upon anti-<z:chebi fb="6" ids="28384">vitamin K</z:chebi> agents </plain></SENT>
</text></document>